Brian Boyle, MD

Psychiatric Neurotherapeutics Program, McLean Hospital, Belmont, Massachusetts; Department of Psychiatry, Harvard Medical School, Boston, Massachusetts

  • 1Article
  • 5.1KReads1
  • 2025Active
  • 8Collaborators
  • 6Citations2

1 Read counts for articles published before 2020 may include some non-human traffic.

2 Citation counts provided by Crossref.

About

Brian Boyle, MD, is affiliated with the Psychiatric Neurotherapeutics Program at McLean Hospital and the Department of Psychiatry at Harvard Medical School. His work focuses on treatment-resistant depression, specifically examining the comparative effects of repeated ketamine infusion versus intranasal esketamine. Boyle has contributed to research published in Psychiatrist.com, collaborating with co-authors including Amanda Sedgewick and Robert Meisner.

Publications

JCP
Comparative Effects of Repeated Ketamine Infusion vs Intranasal Esketamine in Patients with Treatment Resistant Depression: A Retrospective Chart Review
Original Research

Comparative Effects of Repeated Ketamine Infusion vs Intranasal Esketamine in Patients with Treatment Resistant Depression: A Retrospective Chart Review

September 22, 2025

In this naturalistic sample of patients with similarly severe treatment resistant depression treated over a 4- to 5-week induction period, intravenous racemic ketamine was associated with more rapid response...
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Ketamine and Psychedelics

Listen to the Podcast
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe